Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva Lowers Forecast As Q3 Revenues Decline Amid Growing Generic Competition
But Opioid Crisis Settlement On Track
Nov 03 2022
•
By
Ayisha Sharma
Teva's Profits Have Dipped Despite Lower R&D Spend • Source: Shutterstock
Keep up with the top pharma business news of the week. On the go.
Scrip brings you a weekly bulletin of top picks.
More from Business
More from Scrip